Combination Biological and Chemotherapy for Advanced Pancreatic Cancer
Name of the Trial
Why Is This Trial Important?
The chemotherapy drug gemcitabine (Gemzar) is a commonly used treatment for advanced pancreatic cancer, but its benefits are minimal. Researchers hope that adding cetuximab (Erbitux), a monoclonal antibody, to gemcitabine will result in an improved response.
Early clinical work with cetuximab has shown that it does have some effectiveness against pancreatic cancer. Cetuximab binds to cancer cells and blocks a protein called epidermal growth factor receptor (EGFR). EGFR is found in abnormally high amounts on the surface of many types of cancer cells, causing the cells to divide excessively in the presence of epidermal growth factor proteins.
"Currently there is no satisfactory treatment for pancreatic cancer," said Dr. Philip. "This trial employs a novel targeted therapy that blocks EGFR, hopefully resulting in cancer cells that are less likely to proliferate, more sensitive to chemotherapy, and more prone to apoptosis, or cell death."
Who Can Join This Trial?
Where Is This Trial Taking Place?
Who to Contact
An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.